Anthony Verachtert
Optometrist · Kansas City, MONPI 1417995069
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,525 of the $2,425 with a category attached, or 62.9%. 12 manufacturers reported payments, led by Dompe US, Inc. at 37.1% of the total. Reporting peaked in 2020 at $970 and has fallen 65.0% since, to $339 in 2025.
Across 38 payments — averaging $63.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$900
- Alcon$503
- AbbVie$191
- Rayner Intraocular Lenses Limited$177
- Bausch & Lomb Americas Inc.$170
- Glaukos Corporation$166
- plus $319 from 6 others
Across 96 payments — averaging $9969.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$353K
- Sight Sciences, Inc.$293K
- Oyster Point Pharma, Inc.$226K
- Dompe US, Inc.$44K
- Novartis$33K
- Shire North American Group Inc$7K
- plus $609 from 1 others
What the payments were for
- Speaking & faculty fees$90037%
- Food & beverage$1,52563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 1 | $900 |
| Alcon | 8 | $503 |
| AbbVie(2 entities) | 5 | $191 |
| Rayner Intraocular Lenses Limited | 1 | $177 |
| Bausch & Lomb Americas Inc. | 5 | $170 |
| Glaukos Corporation | 7 | $166 |
| Sun Pharmaceutical Industries Inc. | 2 | $146 |
| Johnson & Johnson Vision Care, Inc. | 2 | $67 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $49 |
| Novartis | 2 | $25 |
| Rxsight Inc | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$900
- Wavelight Refractive Suite$290
- RAYNER CATARACT SET 1$177
- RayOne EMV$177
- RayOne Spheric$177
- RayOne Aspheric$177
- AcrySof$148
- VUITY$114
- CEQUA$112
- MIEBO$110
- XIIDRA$110
How this compares
$2,425 in reported general payments places this provider in the 80th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $62,800 |
| LumiganBimatoprost | 31 | $13,386 |
| Travoprost | 44 | $7,669 |
| TyrvayaVarenicline Tartrate | 11 | $7,365 |
| Cyclosporine | 16 | $5,576 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $4,168 |
| Prednisolone Acetate | 107 | $4,055 |
| Latanoprost | 257 | $2,333 |
| ValacyclovirValacyclovir Hcl | 19 | $1,131 |
| Doxycycline Hyclate | 19 | $818 |
| Acyclovir | 19 | $751 |
| Fluorometholone | 13 | $734 |
| Timolol Maleate | 75 | $687 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 42 | $391 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $191 | $76,18684 claims |
| AlconSimbrinza | $503 | $4,16821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Kansas City
- Geoffrey PowellKansas City$55K
- Michael MooreKansas City$18K
- Kristen YatesKansas City$12K
- Crystal RemingtonKansas City$10K
- Kelsey KleinsasserKansas City$10K
- Lynn GastonKansas City$8K
- Kelli SmithKansas City$7K
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Alana KellerWildwood$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.